跳至主要内容
临床试验/TCTR20210730004
TCTR20210730004已完成不适用

Therapeutic Effectiveness and Safety Outcomes of Generic and Original Imipenem/Cilastatin in Hospitalized Patients: a multicenter non-inferiority study in Thailand

Siam Pharmaceutical Co., Ltd.0 个研究点目标入组 441 人开始时间: 2021年7月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
441

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • (1)Patients aged 18 years or above admitted to the hospital
  • (2)Patients received imipenem/cilastatin (Tienam or Sianem)

排除标准

  • (1)Patient s medical records were not available.
  • (2)Patients received imipenem/cilastatin less than 48 hours.
  • (3)Patients received both generic and original imipenem/cilastatin continuously within the same admission.
  • (4)Patient received carbapenems 14 days prior to the study.
  • (5)Antimicrobial susceptibility testing demonstrating imipenem/cilastatin or carbapenems resistance among the suspected or definite pathogens.
  • (6)Patient died within 48 hours after treatment.

研究者

发起方
Siam Pharmaceutical Co., Ltd.

相似试验

Therapeutic Effectiveness and Safety Outcomes of... | 临床试验